Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors

Vaccine ◽  
2017 ◽  
Vol 35 (4) ◽  
pp. 577-585 ◽  
Author(s):  
Emmanuelle Schaedler ◽  
Christelle Remy-Ziller ◽  
Julie Hortelano ◽  
Nadine Kehrer ◽  
Marie-Christine Claudepierre ◽  
...  
Keyword(s):  
Cancer Vaccine ◽  
Immune Defense ◽  
Tlr9 Ligand ◽  
Sequential Administration

624: Usefulness of Cancer Vaccine Therapy Using Bladder Cancer Cell Line Introduced with Interleukin 21 Gene

2006 ◽  
Vol 175 (4S) ◽  
pp. 201-201 ◽  
Author(s):  
Isao Hara ◽  
Junya Furukawa ◽  
Kazuki Yamanaka ◽  
Yuji Yamada ◽  
Masato Fujisawa
Keyword(s):  
Bladder Cancer ◽  
Cell Line ◽  
Cancer Cell ◽  
Cancer Vaccine ◽  
Cancer Cell Line ◽  
Bladder Cancer Cell ◽  
Vaccine Therapy ◽  
Bladder Cancer Cell Line ◽  
Interleukin 21

Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine

Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
HM Chen ◽  
PH Wang ◽  
SS Chen ◽  
CC Wen ◽  
YH Chen ◽  
...  
Keyword(s):  
Cell Death ◽  
Dendritic Cell ◽  
Tumor Cells ◽  
Cancer Vaccine ◽  
Immunogenic Cell Death

Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old

2019 ◽  
Vol 21 (1) ◽  
pp. 7-19 ◽  
Keyword(s):  
Alzheimer Disease ◽  
Cognitive Aging ◽  
Oldest Old ◽  
Adaptive Immune Response ◽  
Effector T Cells ◽  
Immune Defense ◽  
Supporting Evidence ◽  
Therapeutic Approaches ◽  
Related Data ◽  
Adaptive Immune

Multifaceted evidence supports the hypothesis that inflammatory-immune mechanisms contribute to Alzheimer disease (AD) neuropathology and genetic association of several immune specific genes (TREM2, CR1, and CD33) suggests that maladaptive immune responses may be pivotal drivers of AD pathogenesis. We reviewed microglia-related data from postmortem AD studies and examined supporting evidence from AD animal models to answer the following questions: i) What is the temporal sequence of immune activation in AD progression and what is its impact on cognition? ii) Are there discordant, "primed", microglia responses in AD vs successful cognitive aging? iii) Does central nervous system (CNS) repair in aging depend on recruitment of the elements of cellular adaptive immune response such as effector T cells, and can the recruitment of systemic immune cells ameliorate AD neuropathology? iv) How effective are the immune-system-based therapeutic approaches currently employed for the treatment of AD?

Sign in / Sign up

Export Citation Format

Share Document